Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection

Annals of Surgical Oncology

Volumn 10, Issue 2, 2003, Pages 126-130

  Fant, Jerri S ^a   Grant, Michael D ^a   Knox, Sally M ^a   Livingston, Sheryl A ^a   Ridl, Kimberly ^a   Jones, Ronald C ^a   Kuhn, Joseph A ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Axillary recurrence; Completion axillary dissection; Micrometastasis; Sentinel lymph node

Indexed keywords

EOSIN; HEMATOXYLIN;

ADJUVANT THERAPY; AXILLARY LYMPH NODE; BREAST CANCER; BREAST TUMOR; CELL TYPE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUNG CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MICROSCOPY; PARTIAL MASTECTOMY; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; REVIEW; SENTINEL LYMPH NODE; TIME SERIES ANALYSIS; ARTICLE; AXILLA; FEMALE; PATHOLOGY; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AXILLA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; PHYSICAL EXAMINATION; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

EID: 0038283134     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.04.022     Document Type: Review

References (30)

1. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66:136-8.
2. Kuehn T, Klauss W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients - clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000;64:275-86.
3. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998;339:941-6.
4. Rubio IT, Korourian S, Cowan C, Krag DN, Colvert M, Klimberg VS. Sentinel lymph node biopsy for staging breast cancer. Am J Surg 1998;176:532-7.
5. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
6. Noguchi M. Sentinel lymph node biopsy and breast cancer. Br J Surg 2002;89:21-34.
7. Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg 1999;177:184-7; discussion 188.
8. Hack TF, Cohen L, Katz J, Robson LS, Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 1999;17:143-9.
9. Wong SL, Edwards MJ, Chao C, et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg 2001;136:563-8.
10. Voogd AC, Coebergh JW, Repelaer van Driel OJ, et al. The risk of nodal metastases in breast cancer patients with clinically negative lymph nodes: a population-based analysis. Breast Cancer Res Treat 2000;62:63-9.
11. Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 2001;182:316-20.
12. 11a. Ganaraj A, Kuhn JA, Jones RC, et al. Predictors for nonsentinel node involvement in breast cancer patients with micrometastases in the sentinel lymph node. Baylor University Medical Center Proceedings 2003;16:3-6.
13. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-41.
14. Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001;136:688-92.
15. Furukawa T, Kubota T, Tanino H, et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 2000;20:3657-8.
16. Lenert JT, Vlastos G, Mirza NQ, et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 1999;6:762-7.
17. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304-10.
18. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
19. Baxter N, McCready D, Chapman JA, et al. Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer. Ann Surg Oncol 1996;3:235-40.
20. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
21. Singletary SE. Systemic treatment after sentinel lymph node biopsy in breast cancer: who, what, and why? J Am Coll Surg 2001;192:220-30.
22. Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999;84:138-42.
23. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
24. Cancer research campaign (King's/Cambridge) trial for early breast cancer. A detailed update at the tenth year. Cancer Research Campaign Working Party. Lancet 1980;2:55-60.
25. Lythgoe JP, Palmer MK. Manchester regional breast study - 5 and 10 year results. Br J Surg 1982;69:693-6.
26. Langlands AO, Prescott RJ, Hamilton T. A clinical trial in the management of operable cancer of the breast. Br J Surg 1980;67:170-4.
27. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet 1992;339:1245-8.
28. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol 1999;6:109-16.
29. Bland KI, Scott-Conner CE, Menck H, Winchester DP. Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival. J Am Coll Surg 1999;188:586-95; discussion 595-6.
30. Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Lucy Wortham James clinical research award. Arch Surg 1987;122:1244-7.